Penumbra (PEN) Long-Term Investments (2017 - 2018)

Penumbra (PEN) posted quarterly Long-Term Investments of $2.6 million for Q2 2018, down 20.97% quarter-over-quarter from $3.3 million in Q1 2018.

Penumbra (PEN) Long-Term Investments (2017 - 2018) Analysis & Trends

Penumbra (PEN) has reported Long-Term Investments for 2 consecutive years, with $2.6 million the latest figure, recorded in Q2 2018.

In Q2 2018, Long-Term Investments changed N/A year-over-year to $2.6 million; the TTM figure through Jun 2018 stood at $2.6 million (changed N/A YoY), while the FY2017 annual figure was $3.9 million, changed N/A from the prior year.
Long-Term Investments declined to $2.6 million in Q2 2018 per PEN's latest filing, from $3.3 million in the prior quarter.
Across five years, Long-Term Investments topped out at $3.9 million in Q4 2017 and bottomed at $2.6 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	1.11 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	-
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	-
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	2.25 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	244.10 Mn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	-
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	175.52 Mn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	-
10	Penumbra	12.76 Bn	12.10 Bn	264.94 Mn	-

Download Data